Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.

@article{Ruggenenti2015AntiPhospholipaseAR,
  title={Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.},
  author={Piero Ruggenenti and Hanna Debiec and Barbara Ruggiero and Antonietta Chianca and Timothe{\'e} Pell{\'e} and Flavio Gaspari and Flavio Suardi and Elena Gagliardini and Silvia Orisio and Ariela Benigni and Pierre Ronco and Giuseppe Remuzzi},
  journal={Journal of the American Society of Nephrology : JASN},
  year={2015},
  volume={26 10},
  pages={2545-58}
}
Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary membranous nephropathy (MN), even after other treatments have failed. To assess the relationships among treatment effect, circulating nephritogenic anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies and genetic polymorphisms predisposing to antibody production we serially monitored 24-hour proteinuria and antibody titer in patients with primary MN and long-lasting NS consenting to rituximab (375… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 23 times over the past 90 days. VIEW TWEETS
42 Citations
34 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Similar Papers

Loading similar papers…